Navigation Links
Kendle Announces Third Quarter 2009 Results
Date:11/4/2009

nties include, but are not limited to, (a) competitive factors in the industry, (b) drug-development activity and outsourcing trends in the biopharmaceutical industry, (c) the Company's ability to manage growth, including integration of acquired businesses and implementation of information technology solutions, (d) the Company's dependence on the skills, experience and efforts of its employees and management team in the geographic regions and therapeutic areas in which the Company operates and the risks associated with hiring, managing and retaining members of this team (e) the fixed-price nature of contracts and cost overruns, (f) the loss, cancellation or delay of contracts or amendments thereto, (g) the mix of contracts in the Company's backlog and the sales cycle for these contracts, (h) the Company's ability to service its indebtedness and maintain adequate credit facilities and credit lines, (i) the effects of exchange rate fluctuations, (j) the risks related to the Company's international operations, (k) the amount of goodwill and other intangible assets on the Company's balance sheet and the potential for write-downs of these assets if they become impaired under accounting rules; (l) changes in regulation of the drug-development process, (m) litigation that might arise from patient volunteers in the drug development process, (n) natural disasters, acts of war or other similar events that could have an adverse effect on the Company's operations, and (o) other risks as detailed from time to time in Kendle's Annual Report on Form 10-K as well as periodic reports filed with the SEC. In addition, no assurance can be given that the Company will be able to realize the net service revenues included in backlog. The Company believes that its aggregate backlog is not necessarily a meaningful indicator of future results. All information in this press release is current as of Nov. 4, 2009. The Company undertakes no duty to update any forward-looking statement to conform
'/>"/>
SOURCE Kendle International Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Kendle Announces Details Regarding Second Quarter 2009 Earnings Conference Call and Webcast
2. Kendle to Share Insights at Drug Information Association 45th Annual Meeting
3. Kendle to Present at Upcoming Jefferies and Wachovia Securities Conferences
4. Kendle Announces First Quarter 2009 Earnings Conference Call and Webcast
5. Kendle Expands Asia/Pacific Operations with Opening of Additional Office in India
6. Kendle Revises Full Year 2008 Guidance
7. Kendle to Present at 27th Annual J.P. Morgan Healthcare Conference
8. Kendle Delivers Record Sales, Net Service Revenues and Earnings Per Share for Second Quarter 2008
9. Kendle Delivers Record Net Service Revenues and New Business Authorizations for First Quarter 2008
10. Kendle Promotes Simon S. Higginbotham to President; Appoints Alan J. Boyce as Chief Marketing Officer
11. Kendle Delivers Strong Growth in Revenues, New Business Authorizations and Operating Margin for Full-Year 2007; Announces Guidance for 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... The "North American Interventional ... by Angioplasty Balloon (Plain/Old, Cutting), Stent ... Filter (Retrievable), Endovascular Stent Graft - ... the major market drivers, restraints, and ... , Browse 108 market data tables ...
(Date:8/21/2014)... Rebecca Tabbert, owner of Calimesa Fit Body ... enjoyed watching as more people turn away from the ... camp environment. It’s not only good for her business; ... ‘treadmill-dumbbells-elliptical’ routine just doesn’t work,” she says. “Numerous research ... and lifting those cute little dumbbells does very little ...
(Date:8/21/2014)... Bedros Keuilian’s Annual Fitness Business Summit is considered ... many people already earning seven-figure incomes. But his annual ... open to the owners of Keuilian’s own international fitness boot ... Body Boot Camp World Conference will also be attended by ... camp or are struggling with their own boot camp ...
(Date:8/21/2014)... Chicago, IL (PRWEB) August 21, 2014 ... EB-5 Business & Investment Exploratory Delegation to southern China ... unique opportunity to explore the rapid growing cities of ... each delegate will have the rare opportunity to meet ... their project(s) during a short weeklong time frame. ...
(Date:8/21/2014)... August 21, 2014 mynt welcomes industry ... promoters to join its growing company. Since its pre-launch ... in product sales and continues to gain momentum leading ... , Rob and Tiffanie came into network marketing by ... a number of network marketing companies. Tiffanie needed help ...
Breaking Medicine News(10 mins):Health News:North American Interventional Cardiology and Peripheral Vascular Devices Market worth $5.9 Billion by 2018 - Research Report by MarketsandMarkets 2Health News:North American Interventional Cardiology and Peripheral Vascular Devices Market worth $5.9 Billion by 2018 - Research Report by MarketsandMarkets 3Health News:North American Interventional Cardiology and Peripheral Vascular Devices Market worth $5.9 Billion by 2018 - Research Report by MarketsandMarkets 4Health News:North American Interventional Cardiology and Peripheral Vascular Devices Market worth $5.9 Billion by 2018 - Research Report by MarketsandMarkets 5Health News:Calimesa Fit Body Boot Camp Announces Its Release of a New Video about the Fitness Boot Camp Experience 2Health News:Calimesa Fit Body Boot Camp Announces Its Release of a New Video about the Fitness Boot Camp Experience 3Health News:Fitness Boot Camp Founder Offers Fifty Scholarships to Fit Body Boot Camp World Conference 2Health News:Fitness Boot Camp Founder Offers Fifty Scholarships to Fit Body Boot Camp World Conference 3Health News:Artisan Business Group announces 2014 EB-5 Investment Trade Mission to China 2Health News:Industry Leaders Rob and Tiffanie Moffitt Join mynt 2
... (HealthDay News) -- A combination of animal and human research ... could ultimately help in the treatment of major depression, researchers ... a brain protein known as p11. The study authors cite ... of reward, pleasure and satisfaction with positive life experiences. ...
... its Construction Unit, is participating in and coordinating a ... aim is to develop pest control products with lower ... and less damaging for human health. The two years ... Swedish University of Agricultural Sciences (SLU) and five SME ...
... car increases global temperatures in the long run more ... to a new study. However, in the short run ... because airplanes strongly affect short-lived warming processes at high ... & Technology , a semi-weekly journal. In the ...
... , TUESDAY, Oct. 19 (HealthDay News) -- A small group ... stop taking the cancer drug Gleevec (imatinib) have remained cancer-free ... online Oct. 19 in The Lancet Oncology , is ... go beyond long-term cancer control and offer some patients a ...
... Atlanta, GA, 20 October, 2010 Elsevier / MC ... than 1,300 healthcare organizations, has partnered with the Association ... module for Mosby,s Nursing Skills: Perioperative Collection, the only ... to be consistent with the Standards and Recommended ...
... , WEDNESDAY, Oct. 20 (HealthDay News) -- People with the ... serious eye damage, says a small new study from Greece. ... located near the center of the retina at the back ... vision and the processing of light. In this study, ...
Cached Medicine News:Health News:Animal Study Explores Potential Gene Therapy for Depression 2Health News:Animal Study Explores Potential Gene Therapy for Depression 3Health News:Tecnalia develops environment-friendly and health-friendly pest control products 2Health News:Some With Once-Deadly Leukemia Can Take a Break From Gleevec 2Health News:Some With Once-Deadly Leukemia Can Take a Break From Gleevec 3Health News:Elsevier/MC Strategies and AORN launch perioperative nursing skills collection 2Health News:People With Anorexia May Risk Serious Eye Damage 2
(Date:8/21/2014)... Aug. 21, 2014 CVS Caremark Corporation (NYSE: ... Reference Yields and consideration payable in connection with its previously ... 7, 2014 for (1) any and all of its 6.250% ... (2) up to a maximum amount of its 6.125% Senior ... Senior Notes due 2017 (collectively, the "Maximum Tender Offer Notes" ...
(Date:8/21/2014)... , Aug. 21, 2014  The board of ... a leading provider of clinical trial imaging solutions, today ... named chief financial officer, effective immediately.  Mr. Groff has ... August 2013.  He joined VirtualScopics in January 2006 as ... February 2013. "When the board of VirtualScopics ...
(Date:8/21/2014)... 2014 Professional Compounding Centers of America ... awarding the three best scientific presentations at the ... . The Formulating Better Medicines for Children ... Athens, Greece , includes dozens of ... from which three winners will be selected by ...
Breaking Medicine Technology:CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 2CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 3CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 4CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 5CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 6VirtualScopics, Inc. Names James Groff Chief Financial Officer 2VirtualScopics, Inc. Names James Groff Chief Financial Officer 3VirtualScopics, Inc. Names James Groff Chief Financial Officer 4Professional Compounding Centers of America will award top poster-session winners at European Paediatric Formulation Initiative in Athens 2
... 13, 2007--Active Biotech AB,(Stockholm:ACTI.ST) and Chelsea Therapeutics ... micro-dosing trial of an,I-3D compound. , The ... the pharmacokinetic,characteristics of the compound in humans. ... The study demonstrated that the selected I-3D ...
... 2007 /PRNewswire-FirstCall/ -- CV,Therapeutics, Inc. announced today that ... data from the Ranolazine Open Label,Experience (ROLE) program, ... to be safe and well,tolerated in patients with ... 3 clinical trials, and enrolled in the ROLE,program. ...
Cached Medicine Technology:Active Biotech's I-3D Micro-dosing Clinical Trial Concluded 2JACC Publishes Long-Term Safety and Tolerability Data from,Ranolazine Open Label Experience (ROLE) Program 2JACC Publishes Long-Term Safety and Tolerability Data from,Ranolazine Open Label Experience (ROLE) Program 3JACC Publishes Long-Term Safety and Tolerability Data from,Ranolazine Open Label Experience (ROLE) Program 4
... offers improved ergonomics for today's exacting ... grippy finger rest and the large ... efficiency. Finnpipette Digitals also feature soft-touch ... (pat. pend.) and super blow-out for ...
... AlphaPette Pipettor is the #1 Pipettor ... accuracy, comfort, and reliability. Continuously adjustable. ... readout sub-micrometer. Easy interchangeable ejector buttons ... hands. Adjustable rapid pipet tip ejector ...
... improved ergonomics for today's exacting laboratory ... finger rest and the large display ... Finnpipette Digitals also feature soft-touch tip ... pend.) and super blow-out for 0.2 ...
Research Series 2100 Adjustable-volume Pipette, 10-100 l, single-channel with adjustable-volume setting...
Medicine Products: